


We claim:

1. A compound of Formula I or a salt thereof,



wherein;

R₁ and R₂ are independently selected from the group consisting of: -CH₃, -CH₂CH₃, -CH₂OH, -CH₂OR', -CHO, -CO₂H, and -CO₂R';

- 10 R₃ and R₄ are independently selected from the group consisting of: H, -CH₃, -CH₂CH₃, -CH₂OH, -CH₂OR', -CHO, -CO₂H, and -CO₂R';

- Q is a carbon skeleton selected from the group consisting of: -CH₂-, -CY₁Y₂-, -CH₂CH₂-, -CH=CH-, -CY₁Y₂CY₃Y₄-, -CH₂CH₂CH₂-, -CH=CHCH₂-, -CH=CHCY₁Y₂-, and -CY₁Y₂CY₃Y₄CY₅Y₆-; where Y₁, Y₂, Y₃, Y₄, Y₅, and Y₆ are independently selected
15 from the group consisting of: H, F, Br, Cl, I, OH, OR', and SH; or any one group of Y₁/Y₂, Y₃/Y₄, and Y₅/Y₆ may be =O; or Y₁/Y₃ may form an epoxide; and, at least one of Y₁, Y₂, Y₃, Y₄, Y₅ and Y₆ when present, is not H;



- X₁, X₂, X₃, and X₄ are independently selected from the group consisting of: H, R, OH, -OR, -CO₂H, -CO₂R', F, Br, Cl, I, -CN, -SO₃H, -OSO₃H, NO₂, NH₂, -NHR, and
20 -NR₂; where R is a linear, branched, or cyclic, saturated or unsaturated one to ten carbon alkyl group that is unsubstituted or is substituted with one or more of: OH, =O, SH, F, Br, Cl, I, NH₂, -NHR', -NR'₂, NO₂, -CO₂H, -CO₂R', and epoxide;

- and R' is a linear, branched, or cyclic, saturated or unsaturated one to ten carbon alkyl group that is unsubstituted or substituted with one or more of: OH, =O, SH, F, Br,
25 Cl, I, NH₂, -NHR'', -NR''₂, NO₂ and -CO₂H where R'' is a linear, branched, or cyclic, saturated or unsaturated one to ten carbon alkyl group;



providing that the compound does not have the precise structure of pelorol or any one of the group of structures consisting of:

5

10




15




20

25



and



30

2. The compound of claim 1, wherein $Y_1 - Y_6$ are independently selected from H, F, Br, Cl and I.
3. The compound of claim 1, wherein Q is $-\text{CH}_2-$, $-\text{CH}_2\text{CH}_2-$, $-\text{CH}=\text{CH}-$,
5 $-\text{CH}_2-\text{CH}_2\text{CH}_2-$, or $-\text{CH}=\text{CHCH}_2-$.
4. The compound of claim 1, 2, or 3, wherein the carbon skeleton of Q is saturated.
5. The compound of any one of claims 1-4, wherein the carbon skeleton of Q
10 consists of one or two carbon atoms.
6. The compound of any one of claims 1-5, wherein R_1 is methyl, ethyl, $-\text{CH}_2\text{OH}$, or $-\text{CH}_2\text{OR}'$.
7. The compound of any one of claims 1-6, wherein R_2 is methyl, ethyl, $-\text{CH}_2\text{OH}$, or
15 $-\text{CH}_2\text{OR}'$.
8. The compound of any one of claims 1-7, wherein R' in R_1 is limited to methyl, ethyl, propyl or butyl.
20
9. The compound of any one of claims 1-8, wherein R' in R_2 is limited to methyl, ethyl, propyl or butyl.
10. The compound of claim 8 or 9, wherein R' is limited to methyl or ethyl.
25
11. The compound of any one of claims 1-10, wherein X_1 is H, OH, R, OR, $-\text{CONH}_2$, $-\text{CONHR}'$, or $-\text{COR}'_2$.
12. The compound of any one of claims 1-11, wherein X_2 is H, OH, R, OR, $-\text{CONH}_2$,
30 $-\text{CONHR}'$, or $-\text{COR}'_2$.

13. The compound of any one of claims 1-12, wherein X_3 is H, OH, R, OR, $-\text{CONH}_2$, $-\text{CONHR}'$, or $-\text{COR}'_2$.
14. The compound of any one of claims 1-13, wherein R and R' in one or more of X_1 , X_2 , and X_3 are limited to methyl, ethyl, propyl and butyl.
15. The compound of any one of claims 1-10, wherein X_1 is H, OH, or $-\text{OCH}_3$.
16. The compound of any one of claims 1-10 and 15, wherein X_2 is H, OH, or OCH_3 .
17. The compound of any one of claims 1-10 and 15, wherein X_2 is H, OCH_3 , or $-\text{NHOCH}_3$.
18. The compound of any one of claims 1-10, 15, 16, and 17, wherein X_3 is H, OH, or OCH_3 .
19. The compound of any one of claims 1-18, wherein X_4 is H, R, OH, OR, CO_2H or $\text{CO}_2\text{R}'$.
20. The compound of any one of claims 1-19, wherein R and R' in X_4 are limited to methyl, ethyl, propyl or butyl.
21. The compound of any one of claims 1-18, wherein X_4 is H, R, OH, OCH_3 , $-\text{CO}_2\text{H}$ or $-\text{CO}_2\text{CH}_3$.
22. The compound of claim 1, selected from: homopelorol, dimethoxypelorol, PNSR-4A, PNSR-15A, PNSR-16A, PNSR-17A and PNSR-18A.
23. The compound of any one of claims 1-22, having the configuration S, R, R, S at C-5, C-8, C-9 and C-10 respectively.


24. The compound of any one of claims 1-22, having the configuration R, S, S, R at C-5, C-8, C-9 and C-10 respectively.

25. The compound of any one of claims 1-24, for use as a modulator of SHIP 1 activity.


26. The compound of claim 25, wherein the compound is an agonist of SHIP 1 activity.

27. Use of a compound of any one of claims 1-26 for preparation of a medicament for the treatment or prevention of an inflammatory, neoplastic, hematopoietic or immune disorder or condition.


28. A method of making a compound of Formula IA in which $R_1 - R_4$, X_1 , X_3 and X_4 are as defined in claim 1,




wherein, L' is a C₁ – C₄ saturated or unsaturated alkyl linking group; and A is an activating group; comprising reacting a compound of Formula IIA or IIB:



in which L is absent or is a C₁ – C₃ saturated or unsaturated alkyl linking group and E and E' are electrophilic reactive groups; with a compound of Formula III




in which Nu is a group that renders the compound of Formula III nucleophilic at Nu, followed by optional reduction and by hydrolysis, to produce a compound of Formula IV




and condensing the compound of Formula IV to produce a compound of Formula IA.

29. The method of claim 28, wherein the compounds of Formula IIA and IIB have the structures:



15


30. The method of claim 29, wherein the compounds of Formula IIA and IIB have the structures



30

31. The method of any one of claims 28-30, wherein the compound of Formula IIA or IIB is sclareolide or is derived from sclareolide.

32. The method of any one of claims 28-31, wherein Nu is lithium.
33. The method of any one of claims 28-32, wherein A is OCH₃ or -NHOCH₃.
34. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and one or more compounds of Formula I or pharmaceutically acceptable salts thereof,



wherein;

R₁ and R₂ are independently selected from the group consisting of: -CH₃, -CH₂CH₃, -CH₂OH, -CH₂OR', -CHO, -CO₂H, and -CO₂R';

R₃ and R₄ are independently selected from the group consisting of: H, -CH₃, -CH₂CH₃, -CH₂OH, -CH₂OR', -CHO, -CO₂H, and -CO₂R';

Q is a carbon skeleton selected from the group consisting of: -CH₂-, -CY₁Y₂-, -CH₂CH₂-, -CH=CH-, -CY₁Y₂CY₃Y₄-, -CH₂CH₂CH₂-, -CH=CHCH₂-, -CH=CHCY₁Y₂-, and -CY₁Y₂CY₃Y₄CY₅Y₆-; where Y₁, Y₂, Y₃, Y₄, Y₅, and Y₆ are independently selected from the group consisting of: H, F, Br, Cl, I, OH, OR', and SH; or any one group of Y₁/Y₂, Y₃/Y₄, and Y₅/Y₆ may be =O; or Y₁/Y₃ may form an epoxide; and, at least one of Y₁, Y₂, Y₃, Y₄, Y₅ and Y₆ when present, is not H;

X₁, X₂, X₃, and X₄ are independently selected from the group consisting of: H, R, OH, -OR, -CO₂H, -CO₂R', F, Br, Cl, I, -CN, -SO₃H, -OSO₃H, NO₂, NH₂, -NHR, and -NR₂; where R is a linear, branched, or cyclic, saturated or unsaturated one to ten carbon alkyl group that is unsubstituted or is substituted with one or more of: OH, =O, SH, F, Br, Cl, I, NH₂, -NHR', -NR'₂, NO₂, -CO₂H, -CO₂R', and epoxide;

and R' is a linear, branched, or cyclic, saturated or unsaturated one to ten carbon alkyl group that is unsubstituted or substituted with one or more of: OH, =O, SH, F, Br, Cl, I, NH₂, -NHR'', -NR''₂, NO₂ and -CO₂H where R'' is a linear, branched, or cyclic, saturated or unsaturated one to ten carbon alkyl group.

35. The pharmaceutical composition of claim 34, wherein the one or more compounds of Formula I is not solely pelorol.

36. The pharmaceutical composition of claim 34, comprising pelorol.

5

37. The pharmaceutical composition of claim 34, 35, or 36, comprising a compound according to any one of claims 1-26.

38. A method of prophylaxis or treatment of an immune, hematopoietic, inflammatory
10 or neoplastic disorder or condition comprising administering to a patient in need of said prophylaxis or treatment, an effective amount of a pharmaceutical composition according to any one of claims 34-37.